STAR - Model OLZ - Treatment Of Chemotherapy Induced Nausea And Vomiting (Cinv)

STAR-OLZ is a 5-day transdermal patch in development for the treatment of chemotherapy induced nausea and vomiting (CINV). STAR-OLZ successfully completed Phase 1 human bioavailability studies and is now preparing to advance to a Phase 2 clinical trial. Starton Therapeutics Phase 2 TROPIC-I clinical study will be first to use total control (TC) primary endpoint in superiority study. Total Control is a measure of no nausea, no vomiting, and no rescue medications; existing antiemetics have been approved using a Complete Response (CR) endpoint which only measures vomiting and rescue medications. The standard of care antiemetic regimen for patients treated with highly emetogenic chemotherapy (HEC) results in breakthrough nausea in up to 72% of patients and breakthrough vomiting in up to 50% of patients.